menu
    • menu
    [{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","highestDevelopmentStatusID":"7","companyTruncated":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Series B Financing","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ RA Capital Management"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Lusaris Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Series A Financing","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lusaris Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Lusaris Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Lusaris Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Mebufotenin

    Menu

    Mebufotenin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biomind Labs

                            Canada arrow
                            World Dairy Expo
                            Not Confirmed

                            Biomind Labs

                            Canada arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI

                            Details : 5-MeO-DMT is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 06, 2025

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Cantor Fitzgerald

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            GH Research Announces Pricing of $150 Million Public Offering

                            Details : The procceds will used to fund the clinical development of company's lead product GH001 (mebufotenin), which is being evaluated in patients with bipolar II disorder & other Psychiatry disorder.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 04, 2025

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Cantor Fitzgerald

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Cantor Fitzgerald

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            GH Research Announces Proposed Public Offering

                            Details : The procceds will used to fund the clinical development of company's lead product GH001 (mebufotenin), which is being evaluated in patients with bipolar II disorder & other Psychiatry disorder.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 03, 2025

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Cantor Fitzgerald

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GH Research’s GH001 Meets Primary Endpoint in Phase 2b TRD Trial (-15.5 MADRS)

                            Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of treatment-resistant depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 03, 2025

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

                            Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of treatment-resistant depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 31, 2025

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GH Research Meets Primary Endpoint in Phase 2a Trials of GH001

                            Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of postpartum depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 10, 2025

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

                            Details : 5-Methoxy-N,N-Dimethyltryptamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Biomind Labs

                            Canada arrow
                            World Dairy Expo
                            Not Confirmed

                            Biomind Labs

                            Canada arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biomind Reports Positive Phase 2 Results of BMND08 for Depression in Alzheimer’s Disease

                            Details : BMND08 (5-MeO-DMT) is a 5-HT1A receptor agonist, small molecule drug candidate. It is being evaluated for the treatment of depression & anxiety in alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 29, 2024

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed

                            GH Research

                            Ireland arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant...

                            Details : GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach, which is investigated for the treatment of treatment-resistant depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 29, 2023

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Biomind Labs

                            Canada arrow
                            World Dairy Expo
                            Not Confirmed

                            Biomind Labs

                            Canada arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheime...

                            Details : BMND08 is a proprietary sublingual formulation of 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT"), being investigated as a potential treatment of anxiety and depression in alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 25, 2023

                            Lead Product(s) : Mebufotenin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth